FAGR Fagron SA

Disclosure of notification received from Alychlo

Disclosure of notification received from Alychlo

Regulated information

Nazareth (Belgium)/Rotterdam (The Netherlands), 18 July 2025 – 6 PM CET

Disclosure of notification received from Alychlo

Fagron received a notification based on the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies from Alychlo NV.

Notification by Alychlo NV

  • On 14 July 2025, Fagron received a notification that the shareholding of Alychlo NV, crossed the disclosure threshold of 3% downwards as the result of the disposal of voting securities or voting rights on 25 July 2024.
  • The notification is made by a ‘parent undertaking or a controlling person’.
  • On 25 July 2024 Alychlo NV held a total of 2,139,886 voting rights. In addition, Marc Coucke held 7,047 voting rights.
  • Based on the denominator of 73,228,904 (total number of voting rights) at that time, Alychlo NV and Marc Coucke together held 2.93% of the total number of voting rights on 25 July 2024.
  • The notification of Alychlo NV can be viewed via this .



Further information

Ignacio Artola

Global Investor Relations Leader

About Fagron

Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 30 countries around the world.

Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed by the Dutch company Fagron BV, which is headquartered in Rotterdam.

Important information regarding forward-looking statements

Certain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Attachment



EN
18/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fagron SA

 PRESS RELEASE

Disclosure of notification received from Alychlo

Disclosure of notification received from Alychlo Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 18 July 2025 – 6 PM CET Disclosure of notification received from Alychlo Fagron received a notification based on the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies from Alychlo NV. Notification by Alychlo NV On 14 July 2025, Fagron received a notification that the shareholding of Alychlo NV, crossed the disclosure threshold of 3% downwards as the result of the disposal of voting securities or voting rights on 25 July 2024....

 PRESS RELEASE

Openbaarmaking van kennisgeving ontvangen van Alychlo

Openbaarmaking van kennisgeving ontvangen van Alychlo Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 18 juli 2025 – 18 CET Openbaarmaking van kennisgeving ontvangen van Alychlo Fagron heeft een kennisgeving ontvangen op grond van de Belgische Wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in beursgenoteerde vennootschappen van Alychlo NV. Kennisgeving van Alychlo NV Op 14 juli 2025 ontving Fagron een melding dat het belang van Alychlo NV de meldingsdrempel van 3% had overschreden als gevolg van de verkoop van stemrechtverlenende effecten of s...

Robert Jan Vos ... (+2)
  • Robert Jan Vos
  • Usama Tariq

Fagron N.V. : A serial compounder in the pharma land, we raise our tar...

We’ve raised our medium term estimates for Fagron, expecting mid-term sales growth of 8.3% versus guidance (high single digit), likely topped by 2% via M&A and further supported by rising (AA-OB at 20.8% for 2027) margins (21% by 2027). At ~13.3x (AA-OB) 2026 P/E, Fagron is valued attractively, leading us to raise our target price to €27 per share.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch